Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fennec Pharmaceuticals ( (TSE:FRX) ) has issued an announcement.
Fennec Pharmaceuticals announced a non-brokered private offering of its common shares in Canada, aiming to raise up to US$5,025,000. The offering, targeted at existing institutional shareholders, is expected to close on November 17, 2025, pending necessary approvals. This strategic move could enhance Fennec’s financial position and support its market operations, particularly in the commercialization of its flagship product, PEDMARK®, across various regions.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on TSE:FRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.
Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.
To see Spark’s full report on TSE:FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy. The company is dedicated to the commercialization of PEDMARK®, a product designed to reduce the risk of platinum-induced ototoxicity, which has received regulatory approvals in the U.S., Europe, and the U.K. Fennec has also secured an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI® in Europe, the U.K., Australia, and New Zealand.
Average Trading Volume: 1,137
Technical Sentiment Signal: Buy
Current Market Cap: C$305.6M
For a thorough assessment of FRX stock, go to TipRanks’ Stock Analysis page.